Icon of the Instituts for Quality and Efficiency in Health Care

Dossier assessment

Cabozantinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A17-56
Last updated

Report documents

  1. Extract of dossier assessment

    Cabozantinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 359 kB, EN, not accessible
    Download file : Extract of dossier assessment (PDF document, 359 kB, EN, not accessible)

  2. Dossier assessment

    Cabozantinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 915 kB, DE, not accessible
    Download file : Dossier assessment (PDF document, 915 kB, DE, not accessible)

Dossier assessment

Indication:

Adult patients with advanced renal cell carcinoma following prior vascular endothelial growth factor (VEGF)-targeted therapy

Result of dossier assessment:

Advantage in overall survival and disadvantages regarding side effects; overall indication of minor added benefit

Additional information

Federal Joint Committee (G-BA)

2018-04-05 A G-BA decision was published.

G-BA documents on this decision

Project details

Project no.
A17-56
Commission
Commission awarded on 16.10.2017 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Cancer
Note

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Connected Projects

  1. Dossier assessment

    Cabozantinib (hepatocellular carcinoma) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A18-85
    Last updated

    Status: Commission completed

  2. Dossier assessment

    Cabozantinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A18-37
    Last updated

    Status: Commission completed

  3. Addendum

    Cabozantinib (renal cell carcinoma) - Second Addendum to Commission A17-56

    Project no.
    A18-18
    Last updated

    Status: Commission completed

  4. Addendum

    Cabozantinib (renal cell carcinoma) - Addendum to Commission A17-56

    Project no.
    A18-13
    Last updated

    Status: Commission completed

  5. Dossier assessment

    Cabozantinib - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)

    Project no.
    G14-07
    Last updated

    Status: Commission completed

  6. Dossier assessment

    Cabozantinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A16-69
    Last updated

    Status: Commission completed

  7. Dossier assessment

    Cabozantinib (thyroid carcinoma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V (expiry of the decision)

    Project no.
    G21-20
    Last updated

    Status: Commission completed

  8. Dossier assessment

    Cabozantinib (thyroid carcinoma) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A22-59
    Last updated

    Status: Commission completed

Contact

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form

Print page